Altasciences Wins 2025 CDMO Leadership Award for Small Molecule Dosage
Altasciences, a prominent contract development and manufacturing organization (CDMO), has once again been recognized for its excellence in the pharmaceutical industry. The company, which has previously won the CRO Leadership Award nine times, proudly announces its latest accolade: the 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This award highlights Altasciences’ commitment to supporting drug development with comprehensive services, spanning formulation, manufacturing, and analytical testing, from discovery to commercialization.
The company’s state-of-the-art CDMO site plays a crucial role in drug development, offering a wide range of services to pharmaceutical and biotech firms. Their FDA-inspected facility features Grade C cleanrooms, research and development (R&D) and analytical laboratories, ICH stability chambers, and a current good manufacturing practice (cGMP) warehouse. These resources enable Altasciences to uphold the highest standards of quality, efficiency, and compliance in drug production.
Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences, expressed her appreciation for the recognition, stating, “This award is a testament to the unwavering dedication and expertise of our CDMO team. We remain committed to advancing drug development in collaboration with leading pharmaceutical and biotech innovators. Our integrated solutions ensure that groundbreaking therapeutics reach those who need them faster, and we are grateful for the trust our partners place in us.”
The CDMO Leadership Awards, hosted by Outsourced Pharma, have been a benchmark for excellence in the industry for 14 years. These awards recognize top-performing CDMOs based on extensive industry research and feedback from pharmaceutical and biotech sponsors.
Louis Garguilo, Chief Editor at Outsourced Pharma, commented on this year’s awards, stating, “We are thrilled to introduce the 2025 CDMO Leadership Awards winners to the outsourcing community. Our enhanced scoring methodology and expanded categories provide an improved experience for drug sponsors seeking the right CDMO partner. This distinction is highly coveted, and we are honored to facilitate informed decision-making for the industry.”
Altasciences has built a strong reputation for its expertise in formulating, testing, and manufacturing nearly every pharmaceutical dosage form available on the market. The company’s capabilities include the production of tablets, liquid- and powder-filled capsules, over-encapsulated capsules, nanomilled suspensions, creams, gels, powders, and terminally sterilized injectables.
With a fully integrated approach to drug development, Altasciences’ CDMO facility supports all phases of drug development, from early-stage formulation to late-phase scale-up and commercial manufacturing. The company ensures batch consistency through rigorous in-house analytical testing and environmental monitoring. By leveraging its extensive expertise and integrated services, Altasciences accelerates the formulation, manufacturing, and analysis processes, facilitating a seamless transition from preclinical to clinical development and expediting the delivery of safe and effective therapeutics.
The pharmaceutical industry continues to evolve rapidly, with increasing demand for reliable and efficient CDMO services. Altasciences remains at the forefront of this industry, helping clients navigate the complexities of drug development while maintaining a focus on quality and innovation. Their ability to streamline processes, optimize production timelines, and maintain regulatory compliance makes them a preferred partner for pharmaceutical and biotech companies worldwide.
Altasciences’ leadership in the CDMO space is further solidified by its commitment to continuous improvement and investment in cutting-edge technologies. The company actively explores advancements in drug formulation techniques, including nanotechnology, complex biologics, and innovative drug delivery systems, ensuring that clients receive the most effective and efficient solutions for their therapeutic products.
Beyond its technical expertise, Altasciences prides itself on fostering strong collaborations with its partners. By maintaining open communication and providing tailored solutions, the company builds long-lasting relationships with clients, ensuring that their specific needs are met at every stage of the drug development process. This client-centric approach has played a pivotal role in Altasciences’ success and industry recognition.
Looking ahead, Altasciences aims to further expand its service offerings and enhance its capabilities in response to the evolving needs of the pharmaceutical and biotech sectors. The company remains dedicated to driving innovation, improving efficiencies, and supporting the development of life-saving therapies.
As Altasciences celebrates its 2025 CDMO Leadership Award, it reaffirms its commitment to excellence in pharmaceutical development and manufacturing. This recognition not only underscores the company’s contributions to the industry but also highlights its pivotal role in bringing novel therapeutics to market efficiently and effectively. With a strong foundation and a forward-thinking approach, Altasciences is well-positioned to continue making a meaningful impact in the world of drug development.
